John Vavricka

John Vavricka

Corporate Officer/Principal en ATEA PHARMACEUTICALS, INC. .

Fortuna: 771 026 $ al 31/05/2026

62 años
Health Technology
Consumer Services

Perfil

John F.
Vavricka
was the founder of Iroko Pharmaceuticals LLC, founded in 2007, serving as President & Chief Executive Officer.
Mr. Vavricka was the founder of Biothea Pharma, Inc., founded in 2015, serving as Chief Executive Officer.
Mr. Vavricka is currently the Chief Commercial Officer at Atea Pharmaceuticals, Inc., starting in 2018.
Former positions include President & Chief Executive Officer at Iroko Pharmaceuticals, Inc., Chief Executive Officer at Iroko Holdings LLC, Vice President-Commercial Operations at Seqirus Vaccines Ltd. from 2003 to 2007, Vice President-Regional Sales at GlaxoSmithKline Pharmaceuticals Ltd. from 2001 to 2003, Vice President-Regional Sales at Smithkline Beecham Pharmaceuticals (India) Ltd. from 1987 to 1999, and Vice President-Commercial Operations at Novartis Vaccines & Diagnostics, Inc. Education includes an undergraduate degree from Northwestern University.

Participaciones conocidas en empresas públicas

EmpresaFechaNúmero de accionesValoraciónFecha de valoración
24/04/2026 165.102 ( 0,21 % ) 771 026 $ 31/05/2026

Cargos activos de John Vavricka

EmpresasCargoInicio
ATEA PHARMACEUTICALS, INC. Corporate Officer/Principal 01/10/2018

Antiguos cargos conocidos de John Vavricka.

EmpresasCargoFin
Director Ejecutivo 01/06/2021
Director Ejecutivo 06/07/2016
Corporate Officer/Principal -
GLAXOSMITHKLINE PHARMACEUTICALS LIMITED Corporate Officer/Principal -
Ventas & Marketing -
Ver el detalle de la experiencia de John Vavricka.

Formación de John Vavricka.

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Relaciones

22

Relaciones de 1er grado

10

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Empresas relacionadas

Empresas privadas10

Health Technology

Health Technology

Health Technology

Health Technology

Consumer Services

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

-40%: Ampliación de plazo extraordinaria
d
:
:
APROVECHAR LA PROMOCIÓN